Unknown

Dataset Information

0

Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins.


ABSTRACT: The TDP-43 proteinopathies, which include amyotrophic lateral sclerosis and frontotemporal dementia, are a devastating group of neurodegenerative disorders that are characterized by the mislocalization and aggregation of TDP-43. Here we demonstrate that RNA-targeting CRISPR effector proteins, a programmable class of gene silencing agents that includes the Cas13 family of enzymes and Cas7-11, can be used to mitigate TDP-43 pathology when programmed to target ataxin-2, a modifier of TDP-43-associated toxicity. In addition to inhibiting the aggregation and transit of TDP-43 to stress granules, we find that the in vivo delivery of an ataxin-2-targeting Cas13 system to a mouse model of TDP-43 proteinopathy improved functional deficits, extended survival, and reduced the severity of neuropathological hallmarks. Further, we benchmark RNA-targeting CRISPR platforms against ataxin-2 and find that high-fidelity forms of Cas13 possess improved transcriptome-wide specificity compared to Cas7-11 and a first-generation effector. Our results demonstrate the potential of CRISPR technology for TDP-43 proteinopathies.

SUBMITTER: Zeballos C MA 

PROVIDER: S-EPMC10576788 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins.

Zeballos C M Alejandra MA   Moore Hayden J HJ   Smith Tyler J TJ   Powell Jackson E JE   Ahsan Najah S NS   Zhang Sijia S   Gaj Thomas T  

Nature communications 20231014 1


The TDP-43 proteinopathies, which include amyotrophic lateral sclerosis and frontotemporal dementia, are a devastating group of neurodegenerative disorders that are characterized by the mislocalization and aggregation of TDP-43. Here we demonstrate that RNA-targeting CRISPR effector proteins, a programmable class of gene silencing agents that includes the Cas13 family of enzymes and Cas7-11, can be used to mitigate TDP-43 pathology when programmed to target ataxin-2, a modifier of TDP-43-associa  ...[more]

Similar Datasets

| S-EPMC10104115 | biostudies-literature
2023-09-28 | GSE244306 | GEO
| PRJNA1022156 | ENA
| S-EPMC10567115 | biostudies-literature
| S-EPMC8583295 | biostudies-literature
| S-EPMC2840283 | biostudies-other
| S-EPMC6885686 | biostudies-literature
| S-EPMC7888715 | biostudies-literature
| S-EPMC7989020 | biostudies-literature
| S-EPMC6377782 | biostudies-literature